Kensey Nash's carotid device:
This article was originally published in Clinica
Kensey Nash is entering the carotid market, after having gained European approval to use its embolic protection system - TriActiv ProGuard - in carotid stenting procedures. The product, which was launched in Europe last year for use in saphenous vein graft procedures, is designed for use in branched anatomy, such as those of the carotid arteries. It prevents material or debris, dislodged during stent procedures, from embolising and causing adverse events such as a heart attack or stroke. The Exton, Pennsylvania company estimates that around 50,000 carotid artery stenting procedures are currently performed worldwide each year, a small percentage of the over 500,000 people who suffer from carotid artery disease. A carotid clinical trial in the US is underway to support FDA clearance of the product.
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.